Trial · NCT00829439
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
NCT00829439, Phase 1, Completed, Boston Children's Hospital; results first posted 2016-11-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome. Trials, record NCT00829439. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00829439
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
- NCT number
- NCT00829439
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 16 participants, actual
- Lead sponsor
- Boston Children's Hospital
- Conditions
- Angelman Syndrome
- Interventions
- Levodopa/Carbidopa (4:1)
- First posted
- 2009-01-27
- Last updated
- 2016-11-21
- Results first posted
- 2016-11-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects. | 1 week |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects. | 1 week | mg/kg/day | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects. | Levodopa/Carbidopa | 15 | mg/kg/day |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Levodopa/Carbidopa 2 mg/kg/Day | 3 | |
| Overall Study | STARTED | Levodopa / Carbidopa 5 mg/kg/Day | 3 | |
| Overall Study | STARTED | Levodopa / Carbidopa 10 mg/kg/Day | 6 | |
| Overall Study | STARTED | Levodopa / Carbidopa 15 mg/kg/Day | 4 | |
| Overall Study | COMPLETED | Levodopa/Carbidopa 2 mg/kg/Day | 3 | |
| Overall Study | COMPLETED | Levodopa / Carbidopa 5 mg/kg/Day | 3 | |
| Overall Study | COMPLETED | Levodopa / Carbidopa 10 mg/kg/Day | 5 | |
| Overall Study | COMPLETED | Levodopa / Carbidopa 15 mg/kg/Day | 4 | |
| Overall Study | NOT COMPLETED | Levodopa/Carbidopa 2 mg/kg/Day | 0 | |
| Overall Study | NOT COMPLETED | Levodopa / Carbidopa 5 mg/kg/Day | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Shaky or Unsteady on feet | Nervous system disorders | Levodopa/Carbidopa | 3 | 16 | 3 |
| other | Vomiting | Gastrointestinal disorders | Levodopa/Carbidopa | 2 | 16 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Levodopa/Carbidopa | ||
| Total, other adverse events | Levodopa/Carbidopa | 5 | 16 |
| Total, serious adverse events | Levodopa/Carbidopa | 0 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00829439
GET https://conductscience.org/api/trials/v1/NCT00829439/registered